The Growth Hormone Deficiency drugs in development market research report provides comprehensive information on the therapeutics under development for Growth Hormone Deficiency, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Growth Hormone Deficiency. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Growth Hormone Deficiency and features dormant and discontinued products.
GlobalData tracks 30 drugs in development for Growth Hormone Deficiency by 28 companies/universities/institutes. The top development phase for Growth Hormone Deficiency is preclinical with ten drugs in that stage. The Growth Hormone Deficiency pipeline has 30 drugs in development by companies and 0 by universities/ institutes. Some of the companies in the Growth Hormone Deficiency pipeline products market are: Changchun GeneScience Pharmaceutical, OPKO Health and Aerami Therapeutics.
The key targets in the Growth Hormone Deficiency pipeline products market include Growth Hormone Receptor (Somatotropin Receptor or GHR), Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Ghrelin Receptor or GHSR), and Growth Hormone Releasing Hormone Receptor (Growth Hormone Releasing Factor Receptor or GHRHR).
See Also:
The key mechanisms of action in the Growth Hormone Deficiency pipeline product include Growth Hormone Receptor (Somatotropin Receptor or GHR) Agonist with 21 drugs in Pre-Registration. The Growth Hormone Deficiency pipeline products include six routes of administration with the top ROA being Subcutaneous and nine key molecule types in the Growth Hormone Deficiency pipeline products market including Recombinant Protein, and Fusion Protein.
Growth Hormone Deficiency overview
Growth hormone deficiency (GHD) is a rare and treatable condition that occurs when the pituitary gland does not produce enough growth hormone (GH). GH is a hormone that stimulates growth and metabolism in the body. GHD can affect children and adults, but it has different effects depending on the age of onset. Children with GHD have short stature, delayed puberty, low bone strength, and other health problems. Adults with GHD may have increased body fat, high cholesterol, low muscle mass, reduced bone density, and impaired quality of life. GHD can be caused by genetic mutations, damage to the pituitary gland or hypothalamus, infections, radiation, or unknown factors. GHD is diagnosed by measuring the levels of GH and other hormones in the blood, as well as performing stimulation tests to check the response of the pituitary gland. Treatment for GHD involves injections of synthetic GH, which can help restore normal growth and metabolism.
For a complete picture of Growth Hormone Deficiency’s pipeline drug market, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
